The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis – an introduction

Freeman, Keith

doi:10.1185/03007995.2010.540985

Cited by 2 publications

(1 citation statement)

References 47 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the basis of the findings of this review, it was found that the best results were obtained with the use of clobetasol propionate in different vehicles (solution, foam and lotion) [29] [30]. When the placebo was compared to calcipotriol, there were better results with calcipotriol [47]- [49]; however, the magnitude of the effect was lower than in relation to clobetasol and It was similar to other corticosteroids, such as valerate of betamethasone, ancinonide, halcinonide, and fluocinolone acetonide. The opposite was observed for psoriasis on the body, which is described a greater efficiency in the association between calcipotriol and betamethasone dipropionate [50].…”

Section: Discussionmentioning

confidence: 99%

Scalp Psoriasis: Systematic Review Comparing Topical Treatments and Placebo

Jales¹,

Hirata²,

Attalah³

et al. 2015

JCDSA

View full text Add to dashboard Cite

Patients with scalp psoriasis suffered from a lower quality of life relating to the highly visible site of their psoriatic lesions. In consequence this fact stimulates investigations involving treatments of this dermatologic disease. The aim of this review is to evaluate the topical treatments for scalp psoriasis compared with placebos. Methods: A systematic review was performed using searches in the database LILACS, MEDLINE, Cochrane Library, and Embase. As selection criteria were chosen eligible publications involving randomized controlled trials, patients with scalp psoriasis diagnosed clinically or by biopsy, interventions with topical treatments for scalp psoriasis compared with placebo. Outcome related to the reduction in severity of psoriasis of the scalp, assessed by physicians and patients, and assessment of adverse effects that required discontinuation of treatment. The results have shown that the patients were aged 12 to 97 years, including 3441 patients. Ten of the fifteen studies included reported gender data. Patients were mostly female. Twelve studies were about psoriasis's severity. These studies in which the severity has been described, the classification of severity was mild (0 study), mild to moderate (1 study), moderate to severe (11 studies) and severe (0 study). In conclusion, topical corticosteroids, calcipotriol, ciclopirox olamine and associations between them are effective in the treatment of scalp psoriasis. Clobetasol propionate (0.05%) was the most effective active ingredient in several vehicles in the induction treatment of scalp psoriasis. R. Jales et al.

show abstract